A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA (mRNA) Vaccine Against Influenza

Go Back to All Clinical Trials

A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA (mRNA) Vaccine Against Influenza

Brief description of study

This is a Phase 3 randomized, blinded study to assess the safety, tolerability, and efficacy of a single dose of a study mRNA vaccine against flu in healthy individuals. Using an mRNA platform for the flu shot can quicken the manufacturing of the vaccine, which increases the likelihood that the vaccine matches the seasonal strains. You will be asked to complete up to 5 in-person clinic visits in Manhattan over a 6-month period.

Clinical Study Identifier: s22-00762

ClinicalTrials.gov Identifier: NCT05540522

Principal Investigator: Lalitha Parameswaran.

Other Investigators: Tamia Davis, Mark J. Mulligan, Ellie R. Carmody, Angelica Cifuentes Kottkamp, Celia Engelson, Irma Noriega.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies